Skip to main content

Table 2 Indications to radical cystectomy after EMDA-MMC treatment

From: ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

Recurrent HGNMIBC, n° of patients (%) 6 (23.1%)
 TaG3 1 (3.8%)
 T1G3 2 (7.7%)
 Cis 1 (3.8%)
 Ta/T1G3 + Cis 2 (7.7%)
Evidence of MIBC, n° of patients (%) 4 (15.4%)
 T2 3 (11.5%)
 T4 1 (3.8%)